EXPERT SUPPORT FOR KARO BIO’S STRATEGIC ROUTE FOR EPROTIROME
STOCKHOLM, Sweden, August 27, 2010. Karo Bio held a well attended seminar on Thursday. Professors Steven E. Nissen and Paul J.P. Kastelein together withDr Jens Kristensen, Karo Bio’s Chief Medical Officer, presented and discussed the rationale in the selected development route for eprotirome and the medical need for more effective treatments of dyslipidemia in high-risk patients with heterozygous familial hypercholesterolemia (HeFH).John J.P. Kastelein is Professor of Medicine and Chairman of the Department of Vascular Medicine at Academic Medical Center in Amsterdam, Netherlands, and